Last reviewed · How we verify

NCT05139459: SICK

Sepsis Characterization in Kilimanjaro

Completed Last updated 21 March 2024
What this trial tests

trial in Sepsis in 499 participants. Completed in 3 November 2023.

Timeline
17 January 2022
Primary endpoint
3 November 2023
3 November 2023

Quick facts

Lead sponsorDuke University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment499
Start date17 January 2022
Primary completion3 November 2023
Estimated completion3 November 2023
Sites1 location across United States

Conditions studied

Sponsor

Duke University

Who can join

10 and older, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to prospectively evaluate the barriers to care, evaluation, clinical practices, and outcomes for patients presenting with sepsis to hospitals in the Kilimanjaro Region of northern Tanzania. This will include an assessment of timing and selection of antimicrobials and administration and volume of intravenous fluids. The study also aims to characterize sepsis sub-types in the epidemiologic context of northern Tanzania using statistical clustering techniques of clinical variables and of host immune response patterns.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Other Duke University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05139459.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing